What Transcode Therapeutics, Inc. does.

TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers. Our lead therapeutic product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA. TTX-MC138 has recently completed a Phase 1a clinical trial. In addition to other RNA-targeted product candidates, we are conducting research and development of a cancer vaccine product candidate and an oncolytic immunotherapy platform.

Polynoma Acquisition . On October 8, 2025, we entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with DEFJ, LLC, a Delaware limited liability company, (“DEFJ”) pursuant to which we acquired 100% of the issued and outstanding membership interests of ABCJ, LLC, a Delaware limited liability company, (“ABCJ”) (such transaction, the “Acquisition”). In the Acquisition, we issued 1,152.9568 shares of our Series A Non-Voting Convertible Preferred Stock (the “Series A Preferred Stock”) to DEFJ. Each share of Series A Preferred Stock is convertible into 10,000 shares of common stock. Prior to the Acquisition, ABCJ was a wholly owned subsidiary of DEFJ and an indirect wholly owned subsidiary of CK Life Sciences Int’l., (Holdings) Inc., a listed entity on the Main Board of the Hong Kong Stock Exchange.

Revenue and profit, by fiscal year.

More on RNAZ.

• Transcode Therapeutics, Inc. summary
• Transcode Therapeutics, Inc. financial statements
• Transcode Therapeutics, Inc. key metrics
• Transcode Therapeutics, Inc. health scores and style box
• Transcode Therapeutics, Inc. earnings
• Transcode Therapeutics, Inc. dividends
• Transcode Therapeutics, Inc. valuation
• Transcode Therapeutics, Inc. ownership and insiders
• Transcode Therapeutics, Inc. peers

Figures from Transcode Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.